Skip to
  1. Homepage
  2. Rare diseases
  3. Search
Simple search

Simple search

(*) mandatory field


Other search option(s)

Immunoglobulin A vasculitis

Synonym(s) Anaphylactoid purpura
Henoch-Schönlein purpura
IgA vasculitis
Purpura rheumatica
Rheumatoid purpura
Prevalence 1-9 / 100 000
Inheritance Not applicable
Age of onset Childhood
  • D69.0
MeSH -
MedDRA -


Disease definition

Schönlein-Henoch purpura (SHP) is a systemic IgA vasculitis that affects small vessels. It is characterized by skin purpura, arthritis, and abdominal and/or renal involvement.


SHP usually affects children and is rare in adults. Annual incidence in children is estimated at between 1/6,660 and 1/4,880, whereas it is estimated at around 1/1,000,000 in adults. The male-to-female ratio is 1.5:1.


SHP is associated with deposition of IgA-dominant immune complexes in arterioles, capillaries, and venules, but the exact etiology remains unknown. Several different bacterial organisms, drugs, foods, and insect bites have been implicated as the initiating factors of the disease.

Diagnostic methods

The diagnosis is based on clinical and histopathological findings. Examination of skin and kidney biopsies reveals tissue deposition of IgA with circulating IgA immune complexes.

Differential diagnosis

Differential diagnoses include other causes of purpura such as thrombopenia, hemopathy or infectious diseases. In adults, Wegener granulomatosis, Churg-Strauss syndrome, microscopic polyangiitis, systemic lupus erythematosus, and mixed cryoglobulinemia (see these terms) should also be considered in the differential diagnosis.

Management and treatment

The treatment is symptomatic. The use of steroids and/or immunosuppressors is controversial but may be considered in case of severe gastrointestinal or renal manifestations.


Gastrointestinal or pulmonary bleeding can be life-threatening. The long term prognosis depends on the extent of the renal involvement. Long term follow-up studies of adult series show that end-stage renal failure may occur in up to one-third of patients.

Expert reviewer(s)

  • Dr Evangeline PILLEBOUT

(*) Required fields.

Attention: Only comments seeking to improve the quality and accuracy of information on the Orphanet website are accepted. For all other comments, please send your remarks via contact us. Only comments written in English can be processed.

Captcha image

Detailed information

Summary information
Review article
Clinical practice guidelines
Article for general public
Get Acrobat Reader
The documents contained in this web site are presented for information purposes only. The material is in no way intended to replace professional medical care by a qualified specialist and should not be used as a basis for diagnosis or treatment.